Access to CAR-T therapy in Latin America: Barriers, gaps, and pathways forward. Jorge Contreras
Semin Immunol. 2026 May 5;82:102029. doi: 10.1016/j.smim.2026.102029. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematological malignancies, offering durable responses in conditions such as diffuse large cell lymphoma, B-cell leukemias and multiple myeloma. However, access to this therapy is still limited in low- and middle-income nations, … Read more